Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Receives Average Rating of "Hold" from Analysts

Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Get Free Report) has been assigned a consensus recommendation of "Hold" from the twenty ratings firms that are presently covering the company, MarketBeat Ratings reports. Two analysts have rated the stock with a sell recommendation, twelve have assigned a hold recommendation and six have given a buy recommendation to the company. The average 12-month price target among analysts that have covered the stock in the last year is $123.22.

A number of research analysts have recently issued reports on ZBH shares. Evercore ISI decreased their target price on Zimmer Biomet from $113.00 to $110.00 and set an "in-line" rating on the stock in a research report on Tuesday, October 1st. Raymond James dropped their price objective on shares of Zimmer Biomet from $128.00 to $123.00 and set an "outperform" rating for the company in a research note on Monday, October 14th. Oppenheimer reduced their price target on Zimmer Biomet from $145.00 to $135.00 and set an "outperform" rating on the stock in a report on Tuesday, October 15th. Canaccord Genuity Group reduced their target price on Zimmer Biomet from $120.00 to $115.00 and set a "hold" rating on the stock in a research report on Tuesday, September 10th. Finally, Wolfe Research assumed coverage on Zimmer Biomet in a research note on Tuesday, September 10th. They issued a "peer perform" rating for the company.

Institutional Investors Weigh In On Zimmer Biomet

Several large investors have recently modified their holdings of the stock. GPS Wealth Strategies Group LLC raised its holdings in Zimmer Biomet by 7.0% during the second quarter. GPS Wealth Strategies Group LLC now owns 2,306 shares of the medical equipment provider's stock worth $250,000 after purchasing an additional 150 shares in the last quarter. Welch Group LLC raised its stake in shares of Zimmer Biomet by 76.3% during the 2nd quarter. Welch Group LLC now owns 5,315 shares of the medical equipment provider's stock worth $577,000 after buying an additional 2,300 shares in the last quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA acquired a new stake in shares of Zimmer Biomet in the 2nd quarter valued at approximately $43,000. Assenagon Asset Management S.A. boosted its stake in shares of Zimmer Biomet by 3.5% in the second quarter. Assenagon Asset Management S.A. now owns 24,286 shares of the medical equipment provider's stock valued at $2,636,000 after buying an additional 815 shares in the last quarter. Finally, Rovin Capital UT ADV raised its position in Zimmer Biomet by 13.6% in the second quarter. Rovin Capital UT ADV now owns 5,397 shares of the medical equipment provider's stock worth $586,000 after acquiring an additional 645 shares in the last quarter. Hedge funds and other institutional investors own 88.89% of the company's stock.

Zimmer Biomet Stock Performance

ZBH stock traded down $1.49 during trading on Wednesday, hitting $106.91. 1,560,837 shares of the company traded hands, compared to its average volume of 1,487,706. The company has a debt-to-equity ratio of 0.38, a current ratio of 1.36 and a quick ratio of 0.70. The stock's 50-day simple moving average is $107.57 and its 200 day simple moving average is $108.84. Zimmer Biomet has a 1 year low of $101.47 and a 1 year high of $133.90. The company has a market cap of $21.28 billion, a PE ratio of 20.33, a P/E/G ratio of 1.99 and a beta of 1.02.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last issued its quarterly earnings data on Wednesday, October 30th. The medical equipment provider reported $1.74 earnings per share for the quarter, hitting analysts' consensus estimates of $1.74. Zimmer Biomet had a net margin of 14.27% and a return on equity of 12.95%. The business had revenue of $1.82 billion during the quarter, compared to the consensus estimate of $1.80 billion. During the same quarter in the prior year, the firm posted $1.65 earnings per share. The company's revenue was up 4.1% compared to the same quarter last year. On average, equities analysts expect that Zimmer Biomet will post 7.99 earnings per share for the current fiscal year.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.